Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Continued ritlecitinib treatment can lead to hair regrowth in some patients with alopecia areata who initially don't respond.

Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.

Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.

The system allows precise control of gene expression in mouse skin, useful for studying skin biology.

Radiofrequency microneedling improves the absorption of topical triamcinolone acetonide, especially with deeper needle insertion.

Regulatory T cells help control the immune system and could lead to new treatments for diseases.

The method accurately measures testosterone metabolites with high sensitivity and low environmental impact.

Controlling transposable elements is crucial for successful tissue regeneration.

The treatment was not recommended due to limited effectiveness and significant side effects.

Ritlecitinib 50 mg effectively promotes and sustains hair regrowth in alopecia areata patients.

Introducing the OTC gene improved symptoms in mice with OTC deficiency.

Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.

N-acetylcysteine may help treat trichotillomania.

RUM-loaded SLN shows promise for treating acne and hair loss topically.

Microneedling radiofrequency improves skin texture and tone by stimulating collagen and elastin.

Ritlecitinib works well and is safe for treating alopecia areata.

Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.

Methotrexate is effective for treating rheumatoid arthritis but requires regular monitoring.

Blocking certain brain processes reduces mating behavior in female rats.

Ritlecitinib effectively regrows hair in severe alopecia areata, especially in adolescents.

The new therapy effectively targets brain tumors while minimizing damage to healthy tissue.

Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.

Trichotillomania is a chronic hair-pulling disorder, more common in females, treated with therapy and sometimes medication.

A new method allows for controlled, long-lasting delivery of retinoic acid through the skin with fewer side effects.

PRS injections can improve knee function and reduce pain for up to a year.

Ritlecitinib effectively regrows hair in adolescents with alopecia areata and is safe.

Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.

Bendamustine combined with tucidinostat may effectively treat adult T-cell leukemia.

IGRT resulted in lower acute toxicity for stage III prostate cancer patients.

Group behavior therapy reduces hair-pulling symptoms more than supportive therapy but has limited long-term effectiveness.